CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

Tonny Veenith; Benjamin A Fisher; Daniel Slade; Anna Rowe; Rowena Sharpe; David R Thickett; Tony Whitehouse; Matthew Rowland; James Scriven; Dhruv Parekh; Sarah J Bowden; Joshua S Savage; Duncan Richards; Julian Bion; Pamela Kearns; Simon Gates.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21251478

Documentos relacionados

  1. CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults.
  2. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.
  3. The Life of SARS-CoV-2 Inside Cells: Replication-Transcription Complex Assembly and Function.
  4. Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen tests.